-
1
-
-
10844264628
-
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors
-
Amador ML, Oppenheimer D, Perea S, Maitra A, Cusati G, Iacobuzio-Donahue C, Baker SD, Ashfaq R, Takimoto C, Forastiere A, Hidalgo M (2004) An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 64:9139-9143
-
(2004)
Cancer Res
, vol.64
, pp. 9139-9143
-
-
Amador, M.L.1
Oppenheimer, D.2
Perea, S.3
Maitra, A.4
Cusati, G.5
Iacobuzio-Donahue, C.6
Baker, S.D.7
Ashfaq, R.8
Takimoto, C.9
Forastiere, A.10
Hidalgo, M.11
-
2
-
-
33646576196
-
Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors
-
Calvo E, Baselga J (2006) Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol 24:2158-2163
-
(2006)
J Clin Oncol
, vol.24
, pp. 2158-2163
-
-
Calvo, E.1
Baselga, J.2
-
3
-
-
28144437798
-
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR
-
Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, Okimoto RA, Sgroi DC, Dahiya S, Muir B, Clark JR, Rocco JW, Vokes EE, Haber DA, Bell DW (2005) Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 11:8105-8108
-
(2005)
Clin Cancer Res
, vol.11
, pp. 8105-8108
-
-
Cohen, E.E.1
Lingen, M.W.2
Martin, L.E.3
Harris, P.L.4
Brannigan, B.W.5
Haserlat, S.M.6
Okimoto, R.A.7
Sgroi, D.C.8
Dahiya, S.9
Muir, B.10
Clark, J.R.11
Rocco, J.W.12
Vokes, E.E.13
Haber, D.A.14
Bell, D.W.15
-
4
-
-
33744551470
-
Novel mutations of epidermal growth factor receptor in localized prostate cancer
-
Douglas DA, Zhong H, Ro JY, Oddoux C, Berger AD, Pincus MR, Satagopan JM, Gerald WL, Scher HI, Lee P, Osman I (2006) Novel mutations of epidermal growth factor receptor in localized prostate cancer. Front Biosci 11:2518-2525
-
(2006)
Front Biosci
, vol.11
, pp. 2518-2525
-
-
Douglas, D.A.1
Zhong, H.2
Ro, J.Y.3
Oddoux, C.4
Berger, A.D.5
Pincus, M.R.6
Satagopan, J.M.7
Gerald, W.L.8
Scher, H.I.9
Lee, P.10
Osman, I.11
-
5
-
-
27144523155
-
Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas
-
Gwak GY, Yoon JH, Shin CM, Ahn YJ, Chung JK, Kim YA, Kim TY, Lee HS (2005) Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. J Cancer Res Clin Oncol 131:649-652
-
(2005)
J Cancer Res Clin Oncol
, vol.131
, pp. 649-652
-
-
Gwak, G.Y.1
Yoon, J.H.2
Shin, C.M.3
Ahn, Y.J.4
Chung, J.K.5
Kim, Y.A.6
Kim, T.Y.7
Lee, H.S.8
-
6
-
-
0025847519
-
Expression of HLA class I and class II in gastric carcinoma in relation to pathologic stage
-
Klein B, Klein T, Nyska A, Shapira J, Figer A, Schwartz A, Rakovsky E, Livni E, Lurie H (1991) Expression of HLA class I and class II in gastric carcinoma in relation to pathologic stage. Tumour Biol 12:68-74
-
(1991)
Tumour Biol
, vol.12
, pp. 68-74
-
-
Klein, B.1
Klein, T.2
Nyska, A.3
Shapira, J.4
Figer, A.5
Schwartz, A.6
Rakovsky, E.7
Livni, E.8
Lurie, H.9
-
7
-
-
20244389231
-
Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck
-
Lee JW, Soung YH, Kim SY, Nam HK, Park WS, Nam SW, Kim MS, Sun DI, Lee YS, Jang JJ, Lee JY, Yoo NJ, Lee SH (2005) Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 11:2879-2882
-
(2005)
Clin Cancer Res
, vol.11
, pp. 2879-2882
-
-
Lee, J.W.1
Soung, Y.H.2
Kim, S.Y.3
Nam, H.K.4
Park, W.S.5
Nam, S.W.6
Kim, M.S.7
Sun, D.I.8
Lee, Y.S.9
Jang, J.J.10
Lee, J.Y.11
Yoo, N.J.12
Lee, S.H.13
-
8
-
-
29144518064
-
Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma
-
Lee SC, Lim SG, Soo R, Hsieh WS, Guo JY, Putti T, Tao Q, Soong R, Goh BC (2006) Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma. Pharmacogenet Genomics 16:73-74
-
(2006)
Pharmacogenet Genomics
, vol.16
, pp. 73-74
-
-
Lee, S.C.1
Lim, S.G.2
Soo, R.3
Hsieh, W.S.4
Guo, J.Y.5
Putti, T.6
Tao, Q.7
Soong, R.8
Goh, B.C.9
-
9
-
-
0037339858
-
Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism
-
Liu W, Innocenti F, Chen P, Das S, Cook EH Jr, Ratain MJ (2003) Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res 9:1009-1012
-
(2003)
Clin Cancer Res
, vol.9
, pp. 1009-1012
-
-
Liu, W.1
Innocenti, F.2
Chen, P.3
Das, S.4
Cook Jr., E.H.5
Ratain, M.J.6
-
10
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
-
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139
-
(2004)
N Engl J Med
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
Gurubhagavatula, S.4
Okimoto, R.A.5
Brannigan, B.W.6
Harris, P.L.7
Haserlat, S.M.8
Supko, J.G.9
Haluska, F.G.10
Louis, D.N.11
Christiani, D.C.12
Settleman, J.13
Haber, D.A.14
-
11
-
-
0030746973
-
HLA-A2 antigen status predicts metastasis and response to immunotherapy in gastric cancer
-
Ogoshi K, Tajima T, Mitomi T, Makuuchi H, Tsuji K (1997) HLA-A2 antigen status predicts metastasis and response to immunotherapy in gastric cancer. Cancer Immunol Immunother 45:53-59
-
(1997)
Cancer Immunol Immunother
, vol.45
, pp. 53-59
-
-
Ogoshi, K.1
Tajima, T.2
Mitomi, T.3
Makuuchi, H.4
Tsuji, K.5
-
12
-
-
32944481596
-
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib
-
Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA (2006) Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12:839-844
-
(2006)
Clin Cancer Res
, vol.12
, pp. 839-844
-
-
Riely, G.J.1
Pao, W.2
Pham, D.3
Li, A.R.4
Rizvi, N.5
Venkatraman, E.S.6
Zakowski, M.F.7
Kris, M.G.8
Ladanyi, M.9
Miller, V.A.10
-
13
-
-
0035975569
-
Alterations of HLA class I and II antigen expression in preinvasive, invasive and metastatic cervical cancers
-
Ryu KS, Lee YS, Kim BK, Park YG, Kim YW, Hur SY, Kim TE, Kim IK, Kim JW (2001) Alterations of HLA class I and II antigen expression in preinvasive, invasive and metastatic cervical cancers. Exp Mol Med 33:136-144
-
(2001)
Exp Mol Med
, vol.33
, pp. 136-144
-
-
Ryu, K.S.1
Lee, Y.S.2
Kim, B.K.3
Park, Y.G.4
Kim, Y.W.5
Hur, S.Y.6
Kim, T.E.7
Kim, I.K.8
Kim, J.W.9
-
14
-
-
23044511620
-
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: A gynecologic oncology group study
-
Schilder RJ, Sill MW, Chen X, Darcy KM, Decesare SL, Lewandowski G, Lee RB, Arciero CA, Wu H, Godwin AK (2005) Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a gynecologic oncology group study. Clin Cancer Res 11:5539-5548
-
(2005)
Clin Cancer Res
, vol.11
, pp. 5539-5548
-
-
Schilder, R.J.1
Sill, M.W.2
Chen, X.3
Darcy, K.M.4
Decesare, S.L.5
Lewandowski, G.6
Lee, R.B.7
Arciero, C.A.8
Wu, H.9
Godwin, A.K.10
-
15
-
-
21344432128
-
Relationship between the downregulation of HLA class I antigen and clinicopathological significance in gastric cancer
-
Shen YQ, Zhang JQ, Miao FQ, Zhang JM, Jiang Q, Chen H, Shan XN, Xie W (2005) Relationship between the downregulation of HLA class I antigen and clinicopathological significance in gastric cancer. World J Gastroenterol 11:3628-3631
-
(2005)
World J Gastroenterol
, vol.11
, pp. 3628-3631
-
-
Shen, Y.Q.1
Zhang, J.Q.2
Miao, F.Q.3
Zhang, J.M.4
Jiang, Q.5
Chen, H.6
Shan, X.N.7
Xie, W.8
-
16
-
-
27544503230
-
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer)
-
Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer). Lancet 366:1527-1537
-
(2005)
Lancet
, vol.366
, pp. 1527-1537
-
-
Thatcher, N.1
Chang, A.2
Parikh, P.3
Rodrigues Pereira, J.4
Ciuleanu, T.5
Von Pawel, J.6
Thongprasert, S.7
Tan, E.H.8
Pemberton, K.9
Archer, V.10
Carroll, K.11
-
17
-
-
11344290086
-
HLA class I antigen down-regulation in primary ovary carcinoma lesions: Association with disease stage
-
Vitale M, Pelusi G, Taroni B, Gobbi G, Micheloni C, Rezzani R, Donato F, Wang X, Ferrone S (2005) HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res 11:67-72
-
(2005)
Clin Cancer Res
, vol.11
, pp. 67-72
-
-
Vitale, M.1
Pelusi, G.2
Taroni, B.3
Gobbi, G.4
Micheloni, C.5
Rezzani, R.6
Donato, F.7
Wang, X.8
Ferrone, S.9
|